Clinical recommendations for diagnosis, treatment and monitoring of patients with invasive breast cancer;Kliničke upute za dijagnozu, liječenje i praćenje bolesnika oboljelih od invazivnog raka dojke

Lijecnicki Vjesnik

Volumn 134, Issue 1-2, 2012, Pages 1-5

  Tomek, Rudolf ^a   Orešković, Lidija Beketić ^a   Vrdoljak, Eduard ^b   Soldić, Željko ^a   Podolski, Paula ^c   Pleština, Stjepko ^c   Gugić, Damir ^d   Vojnović, Željko ^e   Miše, Branka Petrić ^b   Tomić, Snježana ^b   Fajdić, Josip ^f   Vrdoljak, Danko Velimir ^a   Drinković, Ivan ^h   Brkljačić, Boris ^g   Mustać, Elvira ⁱ  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^b Centar za Onkologiju   (Croatia)

^c UNIVERSITY OF ZAGREB   (Croatia)

^d UNIVERSITY HOSPITAL OSIJEK   (Croatia)

^e Varazdin General Hospital   (Croatia)

^f Op a Bolnica Slavonski Brod   (Croatia)

^g University of Zagreb   (Croatia)

^h Klinička Bolnica Dubrava ^*  (Croatia)

ⁱ KBC RIJEKA   (Croatia)

Author keywords

Breast neoplasms Diganosis; Croatia; Pathology; Practice guidelines as topic; Therapy

Indexed keywords

ARTICLE; BREAST TUMOR; FEMALE; HUMAN; PATHOLOGY; PRACTICE GUIDELINE;

BREAST NEOPLASMS; FEMALE; HUMANS;

EID: 84859483919     PISSN: 00243477     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Incidencija raka u Hrvatskoj 2008. Zagreb: Hrvatski zavod za javno zdravstvo. Bilten2010;33.
2. NCCN Clinical Practice Guidelines in Oncology Breast Cancer. 2011. v. 2. http:// www.nccn.org/professionals/physician-gls/PDF/breast.pdf.
3. World Health Organization. World Health Organization histological typing of breast tumors, 2. izd. Am J Clin Pathol 1982;78:806.
4. Greene FL, Page DL, Fleming ID i sur. Breast. U: American Joint Committee on Cancer: AJCC cancer staging manual, 6. izd. New York: Springer; 2002, str. 171.
5. Kataja V, Castiglione M. On behalf of the ESMO Guidelines Working Group. Primary breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20:10-4.
6. Goldhirsch A, Ingle JN, Gelber RD i sur. Tresholds for therapies: Highlights of St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Ann Oncol dci: 10.1093/annonc/ mdp322.
7. Veronesi U, Paganelli G, Viale G A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003;349:546-53. (Pubitemid 36951366)
8. Gnant M, Mlineritsch B, Schippinger W i sur. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360:679-91.
9. Thurlimann B, Price KN, Gelber RD i sur. Is chemotherapy necessary for premenopausal women with lower-risk node positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. Breast Cancer Res Treat 2009;113:137-44.
10. Henderson IC, Berry DA, Demetri GD Improved outcome from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-83. (Pubitemid 46594124)
11. Mamounas EP, Bryant J, Lembersky B i sur. Paclitaxel after doxorubicine plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005;23: 3686-96.
12. Martin M, Pienkowski T, Mackey J Adjuvant docetaxel for nodepositive breast cancer. N Engl J Med 2005;352:2302-13. (Pubitemid 40740554)
13. Jones S, Holmes FA, O'Shaughnessy J i sur. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 2009;27:1155-7.
14. Early Breast Cancer Trialists'Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
15. Clarke M, Collins R, Darby S i sur. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:2087-106.
16. Citron ML, Berry DA, Cirrincione C Randomized trial of dosedense versus conventionally scheduled and sequentional versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21:1431-39. (Pubitemid 46594092)
17. Kyndi M, Overgaard M, Nielsen HM i sur. High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of DBCG 82 b&c. Radiother Oncol 2009;90:74-9.
18. Piccart-Gebhart MJ, Procter M, Leyland-Jones B Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72. (Pubitemid 41464705)
19. Romond EH, Perez EA, Bryant J Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84. (Pubitemid 41464706)
20. Joensuu H, Kellokumpu-Lehtinen P-L, Bono P Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-20. (Pubitemid 43290919)
21. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339:1609-18. (Pubitemid 28536137)
22. Love RR, Van Dinh N, Quy TT i sur. Survival after oophorectomy and tamoxifen in operable breast cancer in premenopausal women. J Clin Oncol 2008;26:253-7.
23. Howell A, Cuzick J, Baum M i sur. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
24. The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-57.
25. Jakesz R, Kaufmann M, Gnant M i sur. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results of ABCSG trial 8 and the ARNO 95 trial. Lancet 2005;366:455-62.
26. Coombes RC, Hall E, Gibson LJ A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92. (Pubitemid 38298988)
27. Goss PE, Ingle JN, Margino S Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG Ma. 17. J Natl Cancer Inst 2005,97:1262-71. (Pubitemid 41535367)
28. Winer EP, Hudis C, Burstein HJ American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005;23: 619-29. (Pubitemid 46224240)
29. Comen EA. Adjuvant hormone therapy: state of the art. Oncology 2009; 23:36-43.
30. Cardoso F, Castiglione M. On behalf of the ESMO Guidelines Working Group: Locally recurrent or metastatic breast cancer: ESMO clinical recommendation for diagnosis, treatment and follow-up. Ann Oncol 2009;20:15-8.
31. Boccardo F, Rubagotti A, Permita A i sur. Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. Ann Oncol 1994;5:337-42.
32. Jonat W, Kaufmann M, Blarney RW i sur. A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. Eur J Cancer 1995;31: 137-42.
33. Klijn JG, Beex LV, Mauriac L Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst 2000;92:903-11. (Pubitemid 30429190)
34. Klijn JG, Blarney RW, Boccardo F Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 2001;19:343-53. (Pubitemid 32112845)
35. Parton M, Smith IE. Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women. J Clin Oncol 2008;26:745-52. (Pubitemid 351264387)
36. Thurlimann B, Paridaens R, Serin D Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group. Eur J Cancer 1997;33: 1767-73. (Pubitemid 28129201)
37. Lonning PE, Bajetta E, Murray R Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000; 18:2234-44. (Pubitemid 30350215)
38. Bertelli G, Garrone O, Merlano M. Sequential use of aromatase inactivators and inhibitors in advanced breast cancer. Proc Am Soc Clin Oncol 2002;21:60.
39. Thurlimann B, Robertson JF, Nabholtz JM Efficacy of tamoxifen following anastrozole ("Arimidex") compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur J Cancer 2003;39:2310-17. (Pubitemid 37214855)
40. Chia S, Piccart M, Gradishar W. Fulvestrant vs exemestane following nonsteroidal aromatase inhibitor failure: first overall survival data from the EFECT trial. Breast Cancer Res Treat 2007; 109: (Abstr 2091).
41. Ghersi D, Wilcken N, Simes RJ. A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer 2005;93: 293-301. (Pubitemid 43080031)
42. Overmoyer B. Options for the treatment of patients with taxane-refractory metastatic breast cancer. Clin Breast Cancer 2008;8:61-70.
43. Ershler WB. Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer. Oncologist 2006; 11:325-35.
44. Geyer CE, Forster J, Lindquist D Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355: 2733-43. (Pubitemid 46021510)
45. Sparano JA, Vrdoljak E, Rixe O i sur. Randomized Phase III trial of ixabepilone plus capecitabine vs capecitabine in patients with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane. J Clin Oncol 2010;28:3256-63.
46. Martin M, Ruiz A, Munoz M i sur. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 2007;8:219-25.
47. Seidman AD, Berry D, Cirrincione C i sur. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 non overexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008;26:1642-9.
48. Slamon DJ, Leyland-Jones B, Shak S Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92. (Pubitemid 32222155)
49. Marty M, Cognetti F, Maraninchi D Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265-74. (Pubitemid 46207001)
50. Spector NL, Xia W, Burris H III i sur. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbBI and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005;23:2502-12. 51.
51. Burris HA III, Hurwitz HI, Dees EC i sur. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005;23:5305-13.
52. Burris HA III. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 2004;9:10-5.
53. Burstein HJ, Storniolo AM, Franco S i sur. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 2008; 19:1068-74.
54. Gomez HL, Doval DC, Chavez MA i sur. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008;26:2999-3005.
55. Cameron D, Casey M, Press M i sur. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112:533-43.
56. Johnston S, Pegram M, Press M i sur. Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): first results from the EGF30008 Trial. Cancer Res 2008;69:74.